Table 1.
mRNA prophylactic vaccines for infectious diseases in clinical trials.
| Product Company/ Institution |
Indication (Disease) | National Clinical Trial Identifier | Active Substance: mRNA | Antigen | Formulation | Phase |
|---|---|---|---|---|---|---|
|
RNActive® CureVac |
Rabies |
NCT02241135 EudraCT 2013-002171-17 |
CV7201 | Rabies virus G protein | Lipid Nanoparticles | 1 |
|
mRNA-1440 Moderna (Valneva) |
Influenza H10N8 |
NCT03076385 EudraCT 2015-003452-48 |
Also referred to as: VAL-506440 | Influenza Hemagglutinin H10N8 (A/Jiangxi-Donghu/346/2013) | Lipid Nanoparticles | 1 |
|
mRNA-1325 Moderna/BARDA |
Zika | NCT03014089 | mRNA-1325 | prM and E | Lipid Nanoparticles | 1 |
|
mRNA-1388 Moderna (Valneva)/ DARPA |
Chikungunya | NCT03325075 | Also referred to as: VAL-181388 | “Viral antigenic proteins” Program appears to have been replaced by mRNA encoding a monoclonal antibody | Lipid Nanoparticles | 1 |
|
mRNA-1653 Moderna |
Human Metapneumovirus and Human Parainfluenza Virus 3 | NCT03392389 | mRNA-1653 | F protein of each virus | Lipid Nanoparticles | 1 |
|
mRNA-1851 Moderna |
Influenza H7N9 | NCT03345043 | Also referred to as: VAL-339851 | (Influenza Hemagglutinin H7N9 A/Anhui/1/2013 | Lipid Nanoparticles | 1 |
|
mRNA-1647 and mRNA-1443 Moderna |
Cytomegalovirus | NCT03382405 | mRNA-1647 and mRNA-1443 | mRNA-1647: gB (1 mRNA), pentameric complex (5 mRNAs), and mRNA-1443 is pp65 | Lipid Nanoparticles | 1 |
|
CV7202 CureVac |
Rabies | NCT03713086EudraCT #: 2017-002856-10 | CV7202 | RABV-G | Lipid Nanoparticles | 1 |
|
mRNA-1893 Moderna/ BARDA |
Zika | NCT04064905 | mRNA-1893 | preM.E with a JEV leader sequence | Lipid Nanoparticles V1GL | 1 |
|
mRNA-1647 Moderna |
CMV (tested in seronegative and seropositive patients) |
NCT04232280 | mRNA-1647 | mRNA-1647: gB (1 mRNA), pentameric complex (5 mRNAs) | Lipid Nanoparticles V1GL | 2 |
|
GSK3903133A GSK |
Rabies | NCT04062669 | Rabies G SAM (CNE) | Rabies G protein (self-amplifying construct) | Lipid Nanoparticles | 1 |
|
mRNA-1653 Moderna |
Human Metapneumovirus and Human Parainfluenza Virus 3 | NCT04144348 | mRNA-1653 | F proteins of each virus | Lipid Nanoparticles V1GL | 1b |
|
mRNA-1345 Moderna |
RSV in older adults | NCT04528719 | mRNA-1345 | Presumed to be F protein based on pre-clinical publications for other earlier Moderna RSV vaccine programs | Lipid Nanoparticles | 1 |